Compare ARCC & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARCC | SNN |
|---|---|---|
| Founded | 2004 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | 16988 |
| Industry | Finance/Investors Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 14.3B |
| IPO Year | 2004 | N/A |
| Metric | ARCC | SNN |
|---|---|---|
| Price | $19.27 | $31.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 2 |
| Target Price | $21.36 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 6.3M | 1.0M |
| Earning Date | 04-28-2026 | 03-16-2026 |
| Dividend Yield | ★ 10.28% | 2.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.77 | $8.58 |
| Revenue Next Year | $2.29 | $5.60 |
| P/E Ratio | $147.35 | ★ $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.40 | $28.02 |
| 52 Week High | $23.42 | $38.79 |
| Indicator | ARCC | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 39.57 |
| Support Level | $18.78 | N/A |
| Resistance Level | $19.43 | $33.89 |
| Average True Range (ATR) | 0.38 | 0.57 |
| MACD | 0.06 | -0.24 |
| Stochastic Oscillator | 85.54 | 18.00 |
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.